Ketamine evokes psychotomimetic symptoms resembling schizophrenia in healthy humans. Imaging markers of acute ketamine challenge have the potential to provide a powerful assay of novel therapies for psychiatric illness. Pharmacological magnetic resonance imaging (phMRI) was conducted in healthy volunteers. The study comprised a control and three ketamine infusion sessions, two of which included pretreatment with lamotrigine or risperidone, compounds hypothesized to reduce ketamine-induced glutamate release. Lamotrigine and risperidone resulted in attenuation of the ketamine-induced increases in signal, including frontal and thalamic regions, demonstrating a ketamine phMRI response that was attenuated with both lamotrigine and risperidone.
See article at J Pharmacol Exp Ther 2013, 345:151–160.
- Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics